Effect of continuous IL-2 administration via the portal vein on growth of liver metastases and cytotoxicity of liver associated mononuclear cells in rats

The aim of this study was no assess the effects of continuous administration of human recombinant interleukin- (rIL-2) via the portal vein on the induction of lymphokine-activated killer (LAK) activity of liver-associated mononuvlear cells, and on the therapeutic activity for hepatic metastases. Donryu rats (8-10 week, male) were inoculated with 1×10^6 AH130 allogenic tumor cells on day 0 via the portal vein, and 2 days later, rIL-2 (50,000 U/day) was administrated continuously via the portal vein (P group), or into the subcutaneous tissue(S group). Control rats were received saline alone (C group). On day 8, the incidence of liver metastases was assessed, and cytotoxisities of blood mononuclear cells (BMC), slenic cells (SC) and non-parenchymal cells of the liver (fraction 1